rct
    2003
    High Quality

    Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial

    De Jesus Moreno Moreno M

    Published in Clinical Therapeutics

    Key Findings

    Choline alfoscerate 1200 mg/day for 180 days improved MMSE and ADAS-Cog scores versus placebo, which worsened.

    Conclusions

    Alpha-GPC improved cognitive outcomes in mild-to-moderate Alzheimer's dementia over 6 months.

    Limitations

    Single indication (AD), industry-linked, no follow-up beyond 6 months.

    Supplements Studied

    Alpha-GPC
    Compound

    Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate.

    Outcomes Measured

    Cognitive Function

    Alpha-GPC improved MMSE and ADAS-Cog cognitive scores over 6 months versus placebo.

    Related Health Concerns

    Cognitive Decline
    Alzheimer's Disease

    Study Details

    Year:2003
    Sample Size:261
    Duration:26 weeks
    Quality Score:8/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.